Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Director | September 08, 2026 | September 08, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director · President, Interim CFO | May 31, 2024 | May 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date September 08, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,800,111 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 784,314 · Balance 2,800,111 F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2030-03-25 | Direct | 0 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 784,314 · Balance 0 F3: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. |
| Common StockSEC Table I · non-derivative | IndirectBy Garret Gallagher - Custodian UTMA/UGMA | 83,000 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 83,000 F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein. F2: These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein.
F2: These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.
Zentalis Pharmaceuticals, Inc.
Report date May 31, 2024 · Filed May 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 633,680 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Sale · Disposed 9,597 · Balance 633,680 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2022 Filed May 31, 2022 20:06 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 111,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000116 · wf-form4_165402754252137.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,885 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 22:52 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $52.70 | $5,270.00 |
DisclosureSEC source: 0001725160-22-000067 · wf-form4_164919913574721.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,813 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 22:52 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,196 | $51.59 | $113,283.08 |
DisclosureSEC source: 0001725160-22-000067 · wf-form4_164919913574721.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,913 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.21 to $52.07. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 22:52 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,335 | $50.68 | $169,009.46 |
DisclosureSEC source: 0001725160-22-000067 · wf-form4_164919913574721.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,109 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.20 to $51.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 22:52 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,369 | $49.72 | $217,206.15 |
DisclosureSEC source: 0001725160-22-000067 · wf-form4_164919913574721.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,444 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.20 to $50.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $43.18 | $4,318.00 |
DisclosureSEC source: 0001725160-22-000061 · wf-form4_164746547616410.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,813 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,322 | $42.31 | $225,177.55 |
DisclosureSEC source: 0001725160-22-000061 · wf-form4_164746547616410.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,913 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $41.78 to $42.755. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,578 | $41.45 | $189,745.74 |
DisclosureSEC source: 0001725160-22-000061 · wf-form4_164746547616410.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,235 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $40.78 to $41.77. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 523 | $45.56 | $23,828.25 |
DisclosureSEC source: 0001725160-22-000057 · wf-form4_164678659275401.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,813 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.55 to $45.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,477 | $44.90 | $425,559.00 |
DisclosureSEC source: 0001725160-22-000057 · wf-form4_164678659275401.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,336 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $44.34 to $45.33. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2022 Filed Feb 15, 2022 23:35 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,370 | $52.74 | $72,249.69 |
DisclosureSEC source: 0001725160-22-000038 · wf-form4_164496810181700.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,813 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.61 to $53.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2022 Filed Feb 15, 2022 23:35 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,366 | $52.15 | $279,852.46 |
DisclosureSEC source: 0001725160-22-000038 · wf-form4_164496810181700.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,183 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.60 to $52.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2022 Filed Feb 15, 2022 23:35 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,264 | $51.22 | $167,192.52 |
DisclosureSEC source: 0001725160-22-000038 · wf-form4_164496810181700.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,549 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.59 to $51.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 02:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,850 | $50.17 | $243,340.02 |
DisclosureSEC source: 0001725160-22-000032 · wf-form4_164489091255122.xml · nonDerivative · entry 5 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,813 F6 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.77 to $50.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 02:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 259 | $50.75 | $13,143.52 |
DisclosureSEC source: 0001725160-22-000032 · wf-form4_164489091255122.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,663 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 02:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,079 | $50.16 | $104,291.37 |
DisclosureSEC source: 0001725160-22-000032 · wf-form4_164489091255122.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,922 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 19,245 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001725160-22-000032 · wf-form4_164489091255122.xml · derivative · entry 6 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,245 Underlying: Common Stock · 19,245 shares Expires 2032-02-09 F8 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 7,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000032 · wf-form4_164489091255122.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,001 F2 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in full on the first anniversary of the grant date. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 8,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000032 · wf-form4_164489091255122.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,406 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 02:53 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,250 | $54.35 | $67,940.50 |
DisclosureSEC source: 0001725160-22-000019 · wf-form4_164428878233215.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.20 to $54.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 02:53 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,460 | $53.51 | $345,686.23 |
DisclosureSEC source: 0001725160-22-000019 · wf-form4_164428878233215.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,453 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.03 to $54.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 02:53 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,290 | $52.77 | $120,847.19 |
DisclosureSEC source: 0001725160-22-000019 · wf-form4_164428878233215.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,913 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.02 to $52.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 00:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,300 | $64.66 | $84,062.03 |
DisclosureSEC source: 0001725160-22-000011 · wf-form4_164263808105131.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.23 to $65.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 00:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,842 | $63.45 | $116,868.64 |
DisclosureSEC source: 0001725160-22-000011 · wf-form4_164263808105131.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,503 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $63.09 to $63.92. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 00:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,424 | $62.37 | $213,544.61 |
DisclosureSEC source: 0001725160-22-000011 · wf-form4_164263808105131.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,345 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $62.01 to $62.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 00:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,434 | $61.71 | $211,900.46 |
DisclosureSEC source: 0001725160-22-000011 · wf-form4_164263808105131.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,769 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.01 to $62.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $78.91 | $7,891.00 |
DisclosureSEC source: 0001725160-22-000004 · wf-form4_164142291575887.xml · nonDerivative · entry 7 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,156 | $78.24 | $90,450.53 |
DisclosureSEC source: 0001725160-22-000004 · wf-form4_164142291575887.xml · nonDerivative · entry 6 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,303 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.76 to $78.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,106 | $76.90 | $85,054.28 |
DisclosureSEC source: 0001725160-22-000004 · wf-form4_164142291575887.xml · nonDerivative · entry 5 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,459 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.68 to $77.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,641 | $76.03 | $276,808.85 |
DisclosureSEC source: 0001725160-22-000004 · wf-form4_164142291575887.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,565 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.62 to $76.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 700 | $75.32 | $52,724.98 |
DisclosureSEC source: 0001725160-22-000004 · wf-form4_164142291575887.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,206 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $74.61 to $75.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 900 | $73.92 | $66,524.04 |
DisclosureSEC source: 0001725160-22-000004 · wf-form4_164142291575887.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,906 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $73.61 to $74.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,397 | $73.18 | $175,407.43 |
DisclosureSEC source: 0001725160-22-000004 · wf-form4_164142291575887.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,806 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $72.59 to $73.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 527 | $78.97 | $41,614.61 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 8 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.81 to $79.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,524 | $78.21 | $119,197.98 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 7 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,730 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.81 to $78.80. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 520 | $77.24 | $40,166.78 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 6 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,254 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.78 to $77.73. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 311 | $76.07 | $23,656.40 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 5 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,774 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.49 to $76.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,117 | $74.50 | $83,213.37 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,085 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $73.95 to $74.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,900 | $73.35 | $139,362.91 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,202 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $72.92 to $73.85. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,100 | $72.01 | $79,210.01 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,102 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $71.69 to $72.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,001 | $71.28 | $213,914.58 |
DisclosureSEC source: 0001725160-21-000240 · wf-form4_163969309168141.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,202 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $70.69 to $71.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 01:35 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 10,000 | $71.33 | $713,300.00 |
DisclosureSEC source: 0001725160-21-000235 · wf-form4_163892730874818.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 986 | $76.67 | $75,593.96 |
DisclosureSEC source: 0001725160-21-000224 · wf-form4_163710784629841.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.49 to $77.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,400 | $75.76 | $181,832.88 |
DisclosureSEC source: 0001725160-21-000224 · wf-form4_163710784629841.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,189 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.48 to $76.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,614 | $75.02 | $496,192.20 |
DisclosureSEC source: 0001725160-21-000224 · wf-form4_163710784629841.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,589 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $74.47 to $75.46. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2021 Filed Nov 6, 2021 01:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,400 | $83.79 | $201,086.40 |
DisclosureSEC source: 0001725160-21-000213 · wf-form4_163616114738577.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $83.54 to $83.99. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2021 Filed Nov 6, 2021 01:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,094 | $82.98 | $422,678.73 |
DisclosureSEC source: 0001725160-21-000213 · wf-form4_163616114738577.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,603 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $82.51 to $83.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2021 Filed Nov 6, 2021 01:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,506 | $82.09 | $205,725.81 |
DisclosureSEC source: 0001725160-21-000213 · wf-form4_163616114738577.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,697 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $81.47 to $82.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 01:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 616 | $67.37 | $41,501.40 |
DisclosureSEC source: 0001725160-21-000201 · wf-form4_163339662219017.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,203 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $67.18 to $67.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 01:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,820 | $66.77 | $321,829.95 |
DisclosureSEC source: 0001725160-21-000201 · wf-form4_163339662219017.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,819 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.18 to $67.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.